The global Buccal Drug Delivery market size is expected to be worth around US$ 8.9 billion by 2030, according to a new report by Vision Research Reports.
The global Buccal Drug Delivery market size was valued at US$ 6.8 billion in 2020 and is anticipated to grow at a CAGR of 10.2% during forecast period 2021 to 2030.
Report Coverage
Report Scope | Details |
Market Size | US$ 8.9 billion by 2030 |
Growth Rate | CAGR of 10.2% From 2021 to 2030 |
Base Year | 2021 |
Forecast Period | 2021 to 2030 |
Segments Covered | Type, Application, End-user |
Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Companies Mentioned | Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; GlaxoSmithKline plc; Indivior Pharmaceuticals; Generex Biotechnology; Catalent; ARx LLC; BioDelivery Sciences International, Inc.; Cynapsus Therapeutics Inc.; Endo Pharmaceuticals plc |
Growth Factors
Buccal drug delivery systems have gained significant momentum since the last decade. Elimination of first-pass metabolism, quick absorption of the pH-sensitive drug, no interaction with stomach acid, quicker onset of action than any oral dose, minimal side effects, and reduced drug degradation are some of the factors fueling the market growth. Buccal drug delivery has gained large acceptance among geriatric patients and patients having difficulty swallowing.
Buccal drug delivery systems have gained significant growth potential due to constant research and development in this field. Compared to oral dosage form, buccal delivery is considered the most convenient and preferred choice, especially among geriatricpatients. This drug delivery route ensures elimination of first pass metabolism, allowing drugs thatarepH sensitive and easily degraded to be administered effectively.
By Type Analysis
The buccal tablets and lozenges segment captured the largest share of over 45.0% in 2020. Increased consumer acceptance, ease of formulation, cost-effectiveness, and wide availability of drug candidates for formulation are the factors responsible for the segment growth.
The sublingual films segment is expected to grow at the highest rate during the forecast period. Factors such as immediate availability of high concentration of drug at a target site and increased research to develop controlled release formulation are responsible for the high growth of the segment.
By End-user Analysis
The hospitals segment dominated the market with a share of over 40.0% in 2020. Increased admission in hospitals, especially of geriatric patients, the abundance of emergency care supplies, and product development and research by various community hospitals are the reasons behind this segment growth.
3 community hospitals in Japan conducted in vitro and in vivo studies to develop mucoadhesive microparticle-laden gels for oral mucositis. The result confirmed the high concentration of the drug at the target site and quicker treatment than traditional dosage forms are likely to improve the adoption.
By Application Analysis
The smoking cessation segment accounted for the largest share of over 31.0% in 2020. Buccal drug delivery is often the most preferred and effective formulation for treating patients with smoking or nicotine addiction.
Increased research to treat sudden cardiac arrest outside hospitals and growing adoption of immediate treatment options have improved the acceptance of sublingual tablets, films, or even injections. This is responsible for the highest growth rate of the angina pectoris segment.
By Regional Analysis
North America dominated the market with a revenue share of over 31.0% in 2020. The presence of a large number of market players, improved research to identify suitable drug candidates, significant investment by large players to improve the development of newer formulations, and improved rate of diagnosis and treatment are the factors boosting the regional market growth.
Asia Pacific is expected to witness the highest growth during the forecast period. A rise in the geriatric population, the growth of the pharmaceutical industry, and an enormous rise in domestic players are likely to boost the regional market growth.
Key Players
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
GlaxoSmithKline plc.
Indivior Pharmaceuticals
Generex Biotechnology
Catalent
ARx LLC
BioDelivery Sciences International, Inc.
Cynapsus Therapeutics Inc.
Endo Pharmaceuticals plc
Market Segmentation
By Type
Sublingual Films
Buccal Tablets and Lozenges
Oral Sprays
By Application
Pain Management
Smoking Cessation
Angina Pectoris
Others
By End-user
Hospitals
Ambulatory Centers
Others
Regional
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Norway
Sweden
Russia
Asia Pacific
China
Japan
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
Turkey
UAE
The Buccal Drug Delivery market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Buccal Drug Delivery market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Buccal Drug Delivery market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Buccal Drug Delivery market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Buccal Drug Delivery market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Buccal Drug Delivery capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Buccal Drug Delivery by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Buccal Drug Delivery market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Buccal Drug Delivery market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Buccal Drug Delivery market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Buccal Drug Delivery industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
Buccal Drug Delivery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Buccal Drug Delivery market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Buccal Drug Delivery market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Buccal Drug Delivery market. These factors have benefited the growth of the global market for Buccal Drug Delivery. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Buccal Drug Delivery. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Buccal Drug Delivery are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Buccal Drug Delivery Market, By Type
7.1. Buccal Drug Delivery Market, by Type, 2021-2030
7.1.1. Sublingual Films
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Buccal Tablets and Lozenges
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Oral Sprays
7.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Buccal Drug Delivery Market, By Application
8.1. Buccal Drug Delivery Market, by Application, 2021-2030
8.1.1. Pain Management
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Smoking Cessation
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Angina Pectoris
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Buccal Drug Delivery Market, By End User
9.1. Buccal Drug Delivery Market, by End User, 2021-2030
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Ambulatory Centers
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Buccal Drug Delivery Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Type (2017-2030)
10.1.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.3. Market Revenue and Forecast, by End User (2017-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.5.3. Market Revenue and Forecast, by End User (2017-2030)
Chapter 11. Company Profiles
11.1. Teva Pharmaceutical Industries Ltd.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Pfizer Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. GlaxoSmithKline plc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Indivior Pharmaceuticals
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Generex Biotechnology
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Catalent
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. ARx LLC
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. BioDelivery Sciences International, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Cynapsus Therapeutics Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Endo Pharmaceuticals plc
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms